Iclusig Heart Attack
Over 5,000 patients in the United States develop chronic myeloid leukemia, a blood cancer, each year, with at least 600 of those dying from the disease. The disease is considered life-threatening, with only a handful of drugs currently on the market which can be used in the treatment of CML. Sales of one of those drugs, Iclusig, was recently suspended in a joint decision by the FDA and the manufacturer of the drug, Ariad Pharmaceuticals. Ariad maintains sales of the drug were suspended only temporarily as the company works with the FDA to determine more accurate dosages and duration periods as well as to design a revised drug label.
Ariad also stresses that Iclusig has not lost its FDA approval or been pulled from the United States Market. Iclusig continues to be sold in Europe, although European regulators have been notified of the most recent clinical safety data. In one clinical trial, consisting of 449 patients, the risk of life-threatening blood clots and severe narrowing of blood vessels was considered significant, with some problems and deaths occurring as soon as two weeks after the patient began taking Iclusig. Some of the people affected were in their twenties and had no other risks of heart disease.
Iclusig is generally seen as a last line of defense in those with chronic myeloid leukemia, used in patients who do not respond to other drugs in this class, including Gleevec. Gleevec targets the overactive tyrosine kinase enzyme present in white blood cells in those with leukemia. In some cases Gleevec allows blood counts to return to normal levels, then the cancer returns, resistant to the drug. Prior to the release of Iclusig, the only recourse for these patients might have been a risky bone marrow transplant. Many of these patients with few options signed up for the Iclusig clinical trials; although one patient likened the side effects of the drug to “a bomb going off in my whole body,” causing intense bone pain for at least the first few days, but the drug has proven effective in some patients.
In phase 2 of the PACE Iclusig trial, about half of the patients responded favorably to the drug. With an eye to gaining even broader approval, Ariad launched a 528-person, phase 3 Iclusig trial last July which tested the drug against Gleevec in those with a new diagnosis of CML. Ariad states there are eight current clinical trials ongoing for Iclusig. Unfortunately, Ariad has experienced a significant setback with the suspension of sales of Iclusig. An FDA spokesperson states the agency is working with Ariad in an attempt to identify the patient populations where the benefits of Iclusig outweigh the risks as well as to further understand the drug’s risks.
Hiring an Iclusig Stroke Lawyer for an Iclusig Stroke Lawsuit
Patients who have suffered such issues as: heart attacks, worsening coronary artery disease, the narrowing of brain arteries, narrowing of blood vessels in arms and legs, congestive heart failure, blood clots in the eye, a decrease in vision, liver failure, hypertensive crisis, blood clots and pancreatitis could possibly benefit from speaking to an Iclusig stroke lawyer. Experienced Iclusig stroke attorneys at the law firm of Sullo & Sullo can assess the individual circumstances of your case, then determine whether an Iclusig stroke lawsuit is in order and the necessary approach to such a lawsuit.
Will We See Iclusig MDL and Iclusig Class Action Lawsuits in the Future?
Like many dangerous drugs and recalled medical devices before Iclusig, it is possible there will be both Iclusig MDL lawsuits as well as Iclusig class action lawsuits in the future on behalf of injured patients. Iclusig MDL lawsuits could prove beneficial for those patients harmed by the drug, who want to ensure the individual details of their specific case will be heard. While Iclusig class action suits split the final settlement equally between the participants, regardless of the level of harm suffered by each individual patient, settlements in an MDL lawsuit are based on the level of harm experienced by the Iclusig patient. MDL litigation allows large numbers of Iclusig lawsuits to be consolidated and heard before a single judge. Discovery, pre-trial hearings, trial scheduling and settlement conferences are held for an entire group of injured patients, allowing the legal process to proceed more quickly and efficiently.
Could You Benefit from Speaking to an Iclusig Heart Attack Lawyer?
Patients who have suffered serious harm such as a heart attack or stroke as a result of taking Iclusig should speak to a knowledgeable Sullo & Sullo attorney in order to have a full understanding of their options. Sullo & Sullo attorneys have compassion for those who have suffered harm from a drug or medical device they believed to be safe. Our attorneys will fight hard to help Iclusig patients receive just compensation for their injuries. Call today for a free evaluation of your Iclusig case.